What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular diseases and restenosis. Intervention: Phosphodiesterase (PDE) inhibitors.

What question did this study set out to answer?

To outline the functional classification of cyclic nucleotide phosphodiesterase isoforms in vascular smooth muscle and explore the therapeutic implications of selective PDE inhibition.

April 1, 1996The Annual Review of Pharmacology and Toxicology

Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle

View Full Paper

Ask AI

Bookmark

Key result

Selective phosphodiesterase inhibitors, particularly PDE3 inhibitors, promote vascular relaxation and possess antiplatelet properties, suggesting potential therapeutic benefits in cardiovascular diseases.

Key Points

To outline the functional classification of cyclic nucleotide phosphodiesterase isoforms in vascular smooth muscle and explore the therapeutic implications of selective PDE inhibition.
Reviewed genetic and functional characteristics across seven mammalian phosphodiesterase (PDE) families comprising more than 30 identified enzymes.
Evaluated physiological responses to isozyme-selective PDE inhibitors in isolated, precontracted, and endothelium-denuded vascular smooth muscle tissues, as well as cell culture models.
Selective inhibition of PDE3 directly triggers relaxation of precontracted vascular smooth muscle independently of functional endothelium.
PDE3 inhibitors exert cardiotonic, antiplatelet, and thrombolytic effects relevant to cardiovascular therapeutics.
Targeted PDE inhibitors switch smooth muscle cells from a proliferative/synthetic phenotype back to a contractile state, indicating efficacy against post-angioplasty restenosis.

Structured PICO

Population

Mammalian tissues and cells, specifically vascular smooth muscle preparations and cultures

Intervention

Phosphodiesterase (PDE) inhibitors, particularly PDE3 inhibitors

Outcome

Vascular relaxation, antiplatelet and thrombolytic activities, and alteration of smooth muscle proliferative phenotype

Selective PDE inhibitors, particularly PDE3 inhibitors, show potential therapeutic benefits in cardiovascular diseases by promoting vascular relaxation and potentially minimizing restenosis after angioplasty.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating for PDE3 inhibition in vascular disease; leaves open confirmation in prospective trials.

Cite This Study

Polson et al. (1996) conducted a review in Cardiovascular diseases and restenosis. Phosphodiesterase (PDE) inhibitors was evaluated. Selective phosphodiesterase inhibitors, particularly PDE3 inhibitors, promote vascular relaxation and possess antiplatelet properties, suggesting potential therapeutic benefits in cardiovascular diseases.

synapsesocial.com/papers/6a1efbd36880c834f2e6b1b0 https://doi.org/10.1146/annurev.pa.36.040196.002155

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider